{"id":22330,"date":"2019-12-19T09:43:31","date_gmt":"2019-12-19T08:43:31","guid":{"rendered":"https:\/\/qlinea.com\/management\/"},"modified":"2026-06-26T09:21:30","modified_gmt":"2026-06-26T07:21:30","slug":"management","status":"publish","type":"page","link":"https:\/\/qlinea.com\/us\/investor-relations\/corporate-governance\/management\/","title":{"rendered":"Management"},"content":{"rendered":"
\r\n
\r\n
\r\n

Management<\/h1>\r\n <\/div>\r\n <\/div>\r\n<\/section>\r\n\n\n\r\n
\r\n
\r\n
\r\n \"\"\r\n <\/div>\r\n
\r\n
\n
\n
Stuart Gander<\/h6>\n
CEO & President<\/h6>\n

Born:<\/strong> 1978<\/p>\n

President since 1 March 2024<\/p>\n

Stuart Gander has worked in the healthcare industry since 2006, advising companies across all sectors while serving with The Boston Consulting Group, where he was Managing Director & Partner. He specialized in medical technologies, working across a wide variety of sectors with an emphasis on medical diagnostics. He has experience working in most major healthcare markets around the world, having lived in nearly equal measure in Europe and North America. Prior to joining Q-linea, he was a member of the executive team at StatLab, a US-based leader in histology, where he held a variety of leadership roles in operations, sales & marketing, R&D and managing its international subsidiaries.<\/p>\n

Education<\/strong>: Graduated with honours from Queen\u2019s University School of Commerce (now Smith) in Kingston, Canada.<\/p>\n<\/div>\n

\n

Other ongoing assignments<\/strong>: No other current assignments.<\/p>\n

Holdings in the Company<\/strong>: 68,444 shares and 40,000 call options, issued by Investment AB \u00d6resund.<\/p>\n<\/div>\n<\/div>\n <\/div>\r\n <\/div>\r\n<\/section>\r\n\n\n\r\n

\r\n
\r\n
\r\n \"\"\r\n <\/div>\r\n
\r\n
Anders Ljunggren
\n<\/strong><\/h6>\n
Deputy CEO<\/h6>\n

Born<\/strong>: 1981<\/p>\n

Employed by the company since 2022, Deputy CEO since March 1 2024<\/p>\n

Anders Ljunggren has extensive experience in engineering project management, having worked at innovative R&D companies in industries like medical devices, industrial applications, consumer electronics, and space technology for the past 15 years. He has a track record of successfully managing B2B and in-house development projects, utilizing cross-functional team management skills and deep understanding of product development. At Q-linea he was responsible for setting up and leading the project management office and establish a portfolio management process as well as a matrix organisation before being promoted to Deputy CEO.<\/p>\n

Education:<\/strong> Masters of Science in Materials Engineering Physics, Uppsala University.
\nOther ongoing assignments:<\/strong> Owner of Coego Consulting AB and Introspection AB. Member of the board of the private estate company BKFAB<\/p>\n

Holdings in the Company<\/strong>:<\/strong> 4,163 shares.<\/p>\n <\/div>\r\n <\/div>\r\n<\/section>\r\n\n\n\r\n

\r\n
\r\n
\r\n \"\"\r\n <\/div>\r\n
\r\n
\n
Annika Blondeau-Henriksson<\/h6>\n<\/div>\n
\n
Interim CFO<\/h6>\n<\/div>\n
\n

Born<\/strong>: 1969<\/p>\n

Interim chief financial officer and investor relations since June 15th<\/sup>\u00a02026.<\/p>\n

Annika Blondeau Henriksson has\u00a0<\/span>extensive experience in leading financial positions and has in recent years worked as interim CFO in various industries including listed companies.<\/span><\/p>\n

Education<\/strong>: Master in Business administration and Economics, Uppsala University.<\/p>\n

Other ongoing assignments<\/strong>: No other current assignments.<\/p>\n

Holdings in the Company<\/strong>: No holdings in the company.<\/p>\n<\/div>\n <\/div>\r\n <\/div>\r\n<\/section>\r\n\n\n\r\n

\r\n
\r\n
\r\n \"\"\r\n <\/div>\r\n
\r\n
\n
Franco Pellegrini<\/h6>\n<\/div>\n
\n
VP Sales, EMEA<\/strong><\/h6>\n<\/div>\n
\n

Born<\/strong>: 1968<\/p>\n

Employed by the Company since 2023<\/p>\n

Franco Pellegrini has more than 20 years of commercial experience in different segments of the Healthcare Market like Cardiac surgery, Radiology and Ultrasound, Minimally Invasive Surgery and Microbiology in both Europe and Unites States.<\/p>\n

Other ongoing assignments<\/strong>: No other current assignments.<\/p>\n

Education<\/strong>: Law Degree from Universit\u00e0 Statale di Milano, Italy.<\/p>\n

Holdings in the Company<\/strong>: 1,000 shares.<\/p>\n<\/div>\n <\/div>\r\n <\/div>\r\n<\/section>\r\n\n\n\r\n

\r\n
\r\n
\r\n \"\"\r\n <\/div>\r\n
\r\n
\n
Henrik Jacobsson<\/h6>\n<\/div>\n
\n
Chief Operating Officer<\/h6>\n<\/div>\n
\n

Born<\/strong>: 1969<\/p>\n

Employed by the Company as Production Manager since 2021, Chief Operating Officer since 2022.<\/p>\n

Henrik has more than 25 years of experience in leading positions mainly in operations and production. He helped create the convenience food concept and the company Gooh where he was responsible for building up the production and logistics operations. This work provided good experience in creating and scaling up the factory and organization. Henrik has also been production director at Lantm\u00e4nnen Cerealia and CEO of Swedish Meat’s subsidiary Esca Food Solutions.<\/p>\n

Education<\/strong>: MSc in Industrial Economics, Link\u00f6ping University.<\/p>\n

Other ongoing assignments<\/strong>: Board member of Jacobson Energi AB, Sk\u00e5nings \u00c5saka Vind AB and Vida Vind AB.<\/p>\n

Holdings in the Company<\/strong>: 3,500 shares.<\/p>\n<\/div>\n <\/div>\r\n <\/div>\r\n<\/section>\r\n\n\n\r\n

\r\n
\r\n
\r\n \"\"\r\n <\/div>\r\n
\r\n
Victoria Lerneryd
\nManager QA\/RA<\/h6>\n

Born<\/strong>: 1984<\/p>\n

Employed by the Company since 2020, Manager QA\/RA since 2020<\/p>\n

Victoria Lerneryd has over 15 years of experience in quality assurance and regulatory affairs within the medical device industry, combining expertise in operational quality assurance, implementing and optimizing quality management systems, and compiling regulatory submissions. Since 2013, she has held leadership roles with responsibility for ensuring compliance with regulatory and quality requirements across the product lifecycle, from development through production and post-market activities, as well as leading regulatory activities and strategies to enable global market access.<\/p>\n

Education<\/strong>: MSc in Chemical Engineering, Uppsala University.
\nOther ongoing assignments<\/strong>: No other current assignments.
\nHoldings in the Company<\/strong>: 2,000 shares.<\/p>\n <\/div>\r\n <\/div>\r\n<\/section>\r\n\n\n\r\n

\r\n
\r\n
\r\n \"\"\r\n <\/div>\r\n
\r\n
Natalie Brown
\nGlobal Marketing Director<\/h6>\n

Born<\/strong>: 1986<\/p>\n

Employed by the Company since 2024, Global Marketing Director since 1 April 2025<\/p>\n

Natalie Brown is passionate about improving healthcare outcomes. She began her career in a breast cancer research lab and later worked on the implantable ports marketing team at C.R. Bard (now BD). Her experience includes working with NGOs in the US, Mexico, and Tanzania, focused on HIV\/AIDS prevention and treatment, free clinic management, and refugee assistance. Prior to joining Q-linea, she was employed by Accelerate Diagnostics for six years, where she held a variety of marketing roles.<\/p>\n

Education<\/strong>: Bachelor of Science in molecular and cellular biology, University of Arizona; Master of Business Administration with healthcare management concentration, University of Arizona.<\/p>\n

Other ongoing assignments<\/strong>: No other current assignments.<\/p>\n

Holdings in the Company<\/strong>: 2,166 shares.<\/p>\n <\/div>\r\n <\/div>\r\n<\/section>\r\n\n\n\r\n

\r\n
\r\n
\r\n \"\"\r\n <\/div>\r\n
\r\n
Ylva Molin
\nManager, Assay<\/h6>\n

Born<\/strong>: 1981<\/p>\n

Employed by the Company since 2012, Manager Assay since January 1 2026<\/p>\n

Ylva Molin has over ten years of experience in product development in medical technology through several leading roles at Q-linea. Ylva possesses a deep and solid knowledge of the company’s products. Previously, Ylva worked at Clinical Microbiology at Uppsala University Hospital. This combination of industrial and clinical backgrounds contributes valuable scientific and operational expertise.<\/p>\n

Education<\/strong>: PhD in infectious diseases, Uppsala University 2010. Biomedicine Program, Uppsala University.<\/p>\n

Other ongoing assignments<\/strong>: No other ongoing assignments.<\/p>\n

Holdings in the Company<\/strong>: 3,407 shares.<\/p>\n <\/div>\r\n <\/div>\r\n<\/section>\r\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":22348,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-22330","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/qlinea.com\/us\/wp-json\/wp\/v2\/pages\/22330","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/qlinea.com\/us\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/qlinea.com\/us\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/qlinea.com\/us\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/qlinea.com\/us\/wp-json\/wp\/v2\/comments?post=22330"}],"version-history":[{"count":10,"href":"https:\/\/qlinea.com\/us\/wp-json\/wp\/v2\/pages\/22330\/revisions"}],"predecessor-version":[{"id":30422,"href":"https:\/\/qlinea.com\/us\/wp-json\/wp\/v2\/pages\/22330\/revisions\/30422"}],"up":[{"embeddable":true,"href":"https:\/\/qlinea.com\/us\/wp-json\/wp\/v2\/pages\/22348"}],"wp:attachment":[{"href":"https:\/\/qlinea.com\/us\/wp-json\/wp\/v2\/media?parent=22330"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}